Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20691336 | 0.90 | RNASEL (0.42) | AHCYADORA2BRNASELFDPSP2RY1 | |
| SCHEMBL20691301 | 0.86 | TYMP (0.47) | AHCYRNASELTYMP | |
| SCHEMBL24444066 | 0.83 | ALDH1A1 (0.42) | TYMP | |
| SCHEMBL20691937 | 0.83 | P2RY1 (0.36) | TYMPFDPSENPP1P2RY1 | |
| SCHEMBL20691938 | 0.78 | HIF1A (0.33) | TYMPENPP1P2RY1 | |
| SCHEMBL22349203 | 0.78 | STING1 (0.38) | TYMP | |
| SCHEMBL22349173 | 0.77 | TYMP (0.33) | TYMP | |
| SCHEMBL20692127 | 0.77 | TYMP (0.33) | TYMP | |
| SCHEMBL21263983 | 0.77 | TAS1R3 (0.36) | TYMP | |
| SCHEMBL20691939 | 0.72 | P2RY1 (0.40) | RNASELFDPSENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | AHCY 1198/4885ADORA2B 1823/4885RNASEL 662/4885 |
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | AHCY 1198/4885ADORA2B 1823/4885RNASEL 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.